Live Breaking News & Updates on Nephrology|Page 4

Stay updated with breaking news from Nephrology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma

1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have a median progression-free survival and overall survival of 22.5 months. Evidence Rating Level: 2 (Good) Study Rundown: Solid organ transplant recipients receiving chronic immunosuppression have an increased risk of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, ....

Rating Level , Cutaneous Squamous Cell Carcinoma , Kidney Transplant , Chronic Disease ,

From viral peptides, small-molecule drugs far beyond infection

Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease. ....

Enyo Pharma Inc , University Of Lyon , Bioworld Science , Endocrine Metabolic , Nonalcoholic Steatohepatitis , Viral Host Interactions , Enyo Pharmaceuticals Inc , Drug Design , Rug Delivery And Technologies ,